Eloralintide

Eli Lilly's selective amylin agonist for weight management — the same hormone axis as cagrilintide and petrelintide. Now in Phase 3 (ENLIGHTEN program) after Phase 2 results in 2025; the "ELO" shorthand circulates outside the trials.

Eloralintide is a selective amylin receptor agonist. Amylin is a hormone co-secreted with insulin from the pancreas that signals satiety through the brainstem — a pathway entirely separate from GLP-1. That separation is the strategic point: because it works through a different receptor system, it can be combined with a GLP-1 agonist to hit satiety from two directions at once, which is where most of the clinical interest sits. Selectivity for the amylin receptor over the related calcitonin receptor is what distinguishes it from earlier amylin analogues.

Phase 2 data reported meaningful weight loss with reported tolerability advantages, which is why it advanced to Phase 3 — but published safety and efficacy evidence remains incomplete while those trials run.

• INVESTIGATIONAL — not approved anywhere. Phase II data has been reported with weight reduction as monotherapy, and combination work with a GLP-1 agonist is the main development interest.
• Its predecessor pramlintide is an approved amylin analogue for diabetes, which establishes the pathway is real in humans — but pramlintide requires frequent injection and carries a boxed warning for severe hypoglycaemia when used with insulin.
• Gastrointestinal adverse effects, principally nausea, appear to be the dominant tolerability issue, as with the amylin class generally.
• Long-term safety and durability are unknown, and no phase III outcome data exists.
• The combination approach — amylin plus GLP-1 — has not established its safety profile at scale.

Given by injection, engineered for a longer duration than pramlintide, which needed dosing with meals. Human pharmacokinetics beyond the trial programme are not publicly characterised. There is no approved product.

Using a drug mid-trial means the safety database is literally still being collected: the known amylin-class pattern (nausea, GI effects) plus whatever Phase 3 exists to find. Any purported product outside a registered study cannot be assumed to contain the investigational drug.

• Everyone outside a clinical trial — it is investigational with no lawful route of access
• Anyone buying something sold under this name online

• Insulin — the amylin class carries a serious hypoglycaemia signal in combination, which is the basis of pramlintide's boxed warning.
• GLP-1 agonists, the intended combination, whose gastrointestinal effects are additive.
• No characterised profile outside the trial setting.

• This is an investigational drug available only through clinical trials, and no monitoring list makes self-directed use appropriate.
• For anyone in a trial: monitoring is defined by the protocol.

Nothing is established about stopping outside the trial setting. As with every satiety-signalling drug studied so far, appetite would be expected to return when the signal stops — that is the pattern across the class rather than a finding specific to this agent.

US: investigational — unapproved, legitimately available only inside Lilly's trials.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
  Lancet, 2025
• Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
  Diabetes Obes Metab, 2026
• Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
  Mol Metab, 2025

• Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of conceptMol Metab · 2025
• Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trialLancet · 2025
• Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of conceptDiabetes Obes Metab · 2026
• Long-acting amylin-related peptides as therapies for obesity and type 2 diabetesPeptides · 2026
• Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversiesMetabol Open · 2026
• Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical TrialsDiabetes Obes Metab · 2026
• Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-AnalysisEndocrinol Diabetes Metab · 2026